Hi leebret! Everything is just great! Thanks. Having a good year so far with my mainly oil portfolio. Trying to stay close to the exits, though. Next month could be a time to jump out.
Acusphere, Inc. (NASDAQ: ACUS) announced that it exceeded the criteria for success for two of the primary endpoints, accuracy and sensitivity, in RAMP-2, its second Phase 3 clinical trial of Imagify injectable suspension.
All three of the ultrasound blinded readers had superior sensitivity and non-inferior accuracy to nuclear stress, the most frequently used imaging procedure for the assessment of coronary artery disease.
Although RAMP-2 did not achieve the specificity endpoint, the Company had previously reported superior specificity for Imagify in its first Phase 3 trial, RAMP-1. High accuracy and sensitivity were the top priorities in RAMP-2.
The Company believes that these results will support a strong NDA submission in Q4 2007.
Imagify is just as accurate, safe, costs only half as much, and takes only a fifth of the time as Nuclear Stress Testing. But, it is still very risky at this time.
"You don't want to sell me death sticks, you want to go home and rethink your life." Obi-Wan Kenobi
Market Data 
Markets 
AI
